Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug spending. But thus far, the data don’t show this.

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug Administration over the agency's decision that Lilly's blockbuster weight-loss and diabetes drugs are no longer in short supply.

GLP-1 weight-loss drugs such as Ozempic and Wegovy are driving down grocery spending, according to a new study from Cornell’s SC Johnson College of Business and consumer data firm Numerator.

Ozempic is a drug for diabetes, but it's also being used off-label for weight loss. Its active ingredient has inspired a new class of weight-loss drugs.

Higher-income households with at least one user of GLP-1 class of weight loss drugs cut their grocery spending by nearly 9%, a recent study based on data from the market research firm Numerator indicates.